Roche Pharma Introduced Clinical Trial Excellence Project

Roche Pharma India announced the commencement of its Clinical Trial Excellence project in India on Tuesday, with the goal of strengthening the ability of public health institutions to conduct clinical trials and drug development in the country. According to a news release, this would also allow these government institutions to become the country's Centres of Excellence for Clinical Research and progress up the value chain.

The Kalyan Singh Super Specialty Cancer Institute (KSSSCI) in Lucknow, Uttar , was the first to join this project with Roche. The Uttar Pradesh government's KSSSCI is a 750-bed state-of-the-art cancer centre that is extensively involved in cancer research and education,according to financial express. "In the first phase of this program, Roche intends to collaborate with ten government hospitals to drive excellence in clinical research by enhancing their existing capabilities for conducting clinical trials in accordance with global standards."

Solutions to enable this include research team training, process development or enhancement, and digitization of dossier submission and review by the Ethics Committee, paving the way for more high quality clinical research focusing on innovative treatments and patient safety," the company said in a statement. According to the company, it has engaged Quinary Clinical Research , a Clinical Research Organization (CRO), to implement the project in India through gap analysis, facilitating upskilling activities through knowledge sharing, training, and workshops, and strengthening capabilities required for conducting world-class clinical trials. India boasts 17% of the world's population, 20% of the world's disease load, and is one of the world's largest providers of trained nurses and experienced physicians.

However, the country accounts for fewer than 1.4% of global clinical trials. This is one of the main reasons why novel drugs are frequently delayed in India, despite the fact that it is an important market with a huge number of patients awaiting treatment.